clinical trial · NCT06976346
Relative Bioavailability Study of HRG2010 in Healthy Subjects
Jiangsu HengRui Medicine Co., Ltd.·phase1·completed·n = 16
Parkinson's DiseaseHRG2010 Capsule, Sinemet®, Madopar®
brief summary
This is a single-center, randomized, open-label, four-period, crossover study. Primary Objective： 1. To evaluate the pharmacokinetic characteristics of healthy subjects after a single oral dose of HRG2010 capsules at dose 1 and dose 2 under fasting conditions, and to compare these with the pharmacokinetic characteristics of Carbidopa/Levodopa Extended-Release Tablets (Sinemet®) and Benserazide/Levodopa Tablets (Madopar®). Secondary Objective 2. To assess safety following administration.
started
Sep 10, 2021
primary completion
Oct 7, 2021
completion
Oct 7, 2021
last updated
May 16, 2025
official title
Pharmacokinetics and Relative Bioavailability Study of HRG2010 Capsule After Single Dose Administration
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol